Chemomab Therapeutics, Scipher Medicine Announce Merger Agreement, Stock Down In Pre-Market
Chemomab Therapeutics (CMMB) and Scipher Medicine agreed to merge, forming a Nasdaq-listed company trading as SCIP. The combined firm will advance nebokitug, an anti-CCL24 antibody, into a Phase 2 rheumatoid arthritis trial. Chemomab holders expected to own ~32% and Scipher ~68%, with contingent value rights. About $30M new funding; cash expected to fund through H2 2028. Deal expected to close Q4 2026; CMMB down to $2.39 pre-market.
How this was made
The 30-second read
Why it matters
The merger announcement provides concrete deal structure (ownership split, CVRs), financing support (about $30M committed by existing investors), and runway (cash through second half of 2028), which should drive valuation and probability-weighted expectations for both pre-close and post-close trading.
Market read
Traders can reassess deal-implied valuation, dilution, and milestone-linked upside for CMMB, while monitoring the transition to the post-close Nasdaq ticker SCIP and the funding runway into 2028.
What to watch
Key missing details for trading include the exchange ratio, exact CVR terms and milestone probabilities, and any regulatory or closing conditions that could delay or derail the Q4 2026 close.
Background
Chemomab and Scipher agreed to merge, aiming to advance nebokitug, a clinical-stage anti-CCL24 antibody, into a Phase 2 rheumatoid arthritis trial.
Ticker impact
Chemomab announced a merger agreement with Scipher, with pre-merger Chemomab holders expected to own about 32% of the combined company.
Likely continued pre-close volatility, with downside risk if deal terms or milestone expectations are viewed skeptically.
The article discloses the merger structure, ownership percentages, CVR mechanics, and that CMMB is down 13.72% pre-market, implying immediate market repricing ahead of Q4 2026 close.
Market effects
Signals continued consolidation in clinical-stage antibody development, with emphasis on advancing CCL24 programs into Phase 2.
Limited direct regional impact; primarily US biotech M&A sentiment.
Moderate, as the deal is US-listed and focused on a specific therapeutic target rather than a global macro driver.
Counterpoint
The sharp pre-market drop in CMMB could be overdone if the market is discounting the CVR and ownership split, while the combined cash runway through H2 2028 reduces near-term financing risk.
Key entities
- companyChemomab Therapeutics Ltd.
Pre-merger equity holders expected to own about 32% of the combined company; CMMB is down 13.72% pre-market.
- companyScipher Medicine Corporation
Pre-merger equity holders expected to own about 68% of the combined company; investors committed about $30M in new funding.
- assetnebokitug
First-in-class clinical-stage anti-CCL24 antibody to be advanced into a Phase 2 rheumatoid arthritis trial.
- investorNorthpond Ventures
Led the group of existing investors committing about $30M in new funding to support the merger.
